Latest period
$2.09B
YoY change
-1.6%
5Y CAGR
-0.1%
Peak year (2024)
$2.21B
Cumulative CapEx
$45.73B
CapEx history chart for Abbott Laboratories (ABT) from 1989 to 2025
Latest: $2.17B
CapEx growth chart for Abbott Laboratories (ABT) from 1989 to 2025
Latest: -1.6%
CapEx history table for Abbott Laboratories (ABT) from 1989 to 2025
| 2025 | $2.17B | -1.6% | −$36.00M | ||
| 2024 | $2.21B | +0.2% | +$5.00M | ||
| 2023 | $2.20B | +23.9% | +$425.00M | ||
| 2022 | $1.78B | -5.7% | −$108.00M | ||
| 2021 | $1.89B | -13.4% | −$292.00M | ||
| 2020 | $2.18B | +32.9% | +$539.00M | ||
| 2019 | $1.64B | +17.5% | +$244.00M | ||
| 2018 | $1.39B | +22.8% | +$259.00M | ||
| 2017 | $1.14B | +1.2% | +$14.00M | ||
| 2016 | $1.12B | +1.0% | +$11.00M | ||
| 2015 | $1.11B | +3.1% | +$33.00M | ||
| 2014 | $1.08B | -5.9% | −$68.00M | ||
| 2013 | $1.15B | -36.2% | −$650.29M | ||
| 2012 | $1.80B | +20.4% | +$303.79M | ||
| 2011 | $1.49B | +46.9% | +$476.43M | ||
| 2010 | $1.02B | -6.8% | −$73.97M | ||
| 2009 | $1.09B | -15.4% | −$198.68M | ||
| 2008 | $1.29B | -22.2% | −$368.48M | ||
| 2007 | $1.66B | +23.8% | +$318.39M | ||
| 2006 | $1.34B | +10.8% | +$130.32M | ||
| 2005 | $1.21B | -6.5% | −$84.14M | ||
| 2004 | $1.29B | +3.6% | +$44.89M | ||
| 2003 | $1.25B | -3.8% | −$49.66M | ||
| 2002 | $1.30B | +11.4% | +$132.69M | ||
| 2001 | $1.16B | +12.3% | +$127.83M | ||
| 2000 | $1.04B | +4.9% | +$48.77M | ||
| 1999 | $987.10M | -20.6% | −$255.60M | ||
| 1998 | $1.24B | +2.7% | +$33.10M | ||
| 1997 | $1.21B | +27.5% | +$260.60M | ||
| 1996 | $949.00M | — | +$949.00M | ||
| 1995 | $0.00 | — | $0.00 | ||
| 1994 | $0.00 | — | $0.00 | ||
| 1993 | $0.00 | -100.0% | −$1.01B | ||
| 1992 | $1.01B | +30.7% | +$236.60M | ||
| 1991 | $770.60M | +20.1% | +$129.20M | ||
| 1990 | $641.40M | +11.9% | +$68.30M | ||
| 1989 | $573.10M | — | — |
- 2025$2.17B-1.6%
- 2024$2.21B+0.2%
- 2023$2.20B+23.9%
- 2022$1.78B-5.7%
- 2021$1.89B-13.4%
- 2020$2.18B+32.9%
- 2019$1.64B+17.5%
- 2018$1.39B+22.8%
- 2017$1.14B+1.2%
- 2016$1.12B+1.0%
- 2015$1.11B+3.1%
- 2014$1.08B-5.9%
- 2013$1.15B-36.2%
- 2012$1.80B+20.4%
- 2011$1.49B+46.9%
- 2010$1.02B-6.8%
- 2009$1.09B-15.4%
- 2008$1.29B-22.2%
- 2007$1.66B+23.8%
- 2006$1.34B+10.8%
- 2005$1.21B-6.5%
- 2004$1.29B+3.6%
- 2003$1.25B-3.8%
- 2002$1.30B+11.4%
- 2001$1.16B+12.3%
- 2000$1.04B+4.9%
- 1999$987.10M-20.6%
- 1998$1.24B+2.7%
- 1997$1.21B+27.5%
- 1996$949.00M—
- 1995$0.00—
- 1994$0.00—
- 1993$0.00-100.0%
- 1992$1.01B+30.7%
- 1991$770.60M+20.1%
- 1990$641.40M+11.9%
- 1989$573.10M—
CapEx values are taken from Abbott Laboratories's reported cash flow statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About CapEx at Abbott Laboratories (ABT)
According to Abbott Laboratories's latest reported financial statements, the company's current CapEx (TTM) is $2.09B. Capital expenditures (CapEx) are cash outlays for property, plant, and equipment and other long-lived productive assets — reported on the cash flow statement under investing activities. CapEx funds future capacity (factories, data centers, software, machinery), so rising spend can signal investment in growth, while heavy CapEx reduces free cash flow available to shareholders. We display CapEx as a positive amount (the absolute cash outflow); compare with revenue to gauge capital intensity and with total assets for the asset-base context.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
As of the 2025 fiscal year, Abbott Laboratories (ABT) reported CapEx of $2.17B – edged down 1.6% year-over-year.
Looking at the 2020–2025 (5 years) stretch, Abbott Laboratories CapEx compounded at -0.1% per year, with a net decline across the window.
Abbott Laboratories CapEx peaked at $2.21B in 2024; the latest annual figure is $2.17B in 2025 (1.6% below peak).
Across the available history, CapEx reached its high of $2.21B in 2024 and its low of $0.00 in 1993.
Abbott Laboratories Capital Expenditures by Year
Abbott Laboratories Capital Expenditures 2025: $2.17B
2025's CapEx for Abbott Laboratories came in at $2.17B, edged down 1.6% below 2024.
Abbott Laboratories Capital Expenditures 2024: $2.21B
Abbott Laboratories posted CapEx of $2.21B in 2024, edged up 0.2% from 2023. This figure represents the highest annual value in the available history.
Abbott Laboratories Capital Expenditures 2023: $2.20B
In 2023, Abbott Laboratories reported CapEx of $2.20B, grew 23.9% from 2022.
Abbott Laboratories Capital Expenditures 2022: $1.78B
Abbott Laboratories CapEx in 2022 was $1.78B, declined 5.7% below 2021.
Abbott Laboratories Capital Expenditures 2021: $1.89B
Abbott Laboratories CapEx in 2021 was $1.89B.
See more financial history for Abbott Laboratories (ABT).
Sector peers by CapEx
Healthcare peers of Abbott Laboratories (ABT), ranked by their latest CapEx
| $14.05B | |
| $7.84B | |
| $4.83B | |
| $4.11B | |
| $3.62B | |
| $2.81B | |
| $1.86B | |
| $1.21B |
- $14.05B
- $7.84B
- $4.83B
- $4.11B
- $3.62B
- $2.81B
- $1.86B
- $1.21B
Frequently asked questions
Abbott Laboratories (ABT) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation